T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.
Highly complicated processes constantly take place in our body to keep pathogens in check: The T-cells of our immune system are busy searching for antigens - suspicious molecules that fit exactly into certain receptors of the T-cells like a key into a lock. This activates the T-cell and the defense mechanisms of the immune system are set in motion.
A drug that boosts the removal of cellular debris in immune cells may increase the protective effects of vaccines in older adults, a study published today in eLife shows.
Scientists have long known that therapies that target the cancer-driving MAPK pathway are only effective in a handful of cancers with specific mutations in a cancer gene called BRAF, and these cancers that initially respond to the therapy often end up developing resistance to the treatment, resulting in relapse for many patients.
Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells' ability to eliminate blood cancers, according to new preclinical data from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center.
A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.
There is an idea within the coronavirus research field that there is some kind of T cell abnormality in critically ill COVID-19 patients, but specific details have not yet been clarified. To shed light on the problem, a research collaboration based in Kumamoto University (Japan) has performed a genetic analysis of T cells from lung tissue of COVID-19 patients.
Researchers have discovered a new "hidden" gene in SARS-CoV-2--the virus that causes COVID-19--that may have contributed to its unique biology and pandemic potential.
Adoptive transfer of T-cells can extend survival and, at times, treat patients with advanced solid tumors.
Scientists have shown that cancer rebuilds the architecture of human chromosomes, which allows the disease to take hold and spread.
Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could be the key to unlocking a new generation of immunotherapies.
Life is an exquisite orchestration of growth and change, with checks and balances that fine-tune complex entwined interactions, both intrinsic and external.
A recent report published in Science Translational Medicine by MUSC Hollings Cancer Center investigator Sophie Paczesny, M.D., Ph.D., sheds light on immune cell biomarkers that may reveal which patients are most at risk for graft-versus-host disease (GVHD), a life-threatening condition that can arise after hematopoietic stem cell transplantation (HSCT) for treatment of liquid cancers such as leukemia.
According to a new study, immune cells that can detect residual HIV-infected cells in patients living with HIV and undergoing ART continue to remain active.
The human body contains a vast number of proteins that are collectively called the proteome.
As Americans begin pulling up their sleeves for an annual flu vaccine, researchers at the University of Wisconsin-Madison have provided new insights into an alternative vaccine approach that provides broader protection against seasonal influenza.
Research led by Dr. Wonmuk Hwang has led to a better understanding of how components of the body's immune system find intruding or damaged cells, which could lead to novel approaches to viral and cancer treatments.
Methicillin-resistant Staphylococcus aureus (MRSA) is the most lethal drug-resistant bacteria and is also one of the most common bacterial pathogens.
Physicians at City of Hope, working in collaboration with scientists at Translational Genomics Research Institute (TGen), have found that greater gut microbial diversity in patients with metastatic kidney cancer is associated with better treatment outcomes on Food and Drug Administration-approved immunotherapy regimens.
Investigators led by a team at Massachusetts General Hospital (MGH) have made discoveries at the single cell level to uncover new details concerning mitochondrial diseases-- inherited disorders that interfere with energy production in the body and currently have no cure.
A Singapore team led by clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) discovered a genetic link to better predict treatment response for relapsed/refractory patients with natural- killer T-cell lymphoma (NKTCL), a highly aggressive form of blood cancer.